Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-02-11

Clinical Trial Update: Specific Use-result Surveillance of Spiriva Respimat in Asthmatics

View source ↗

Summary

A completed post-market surveillance study assessing tiotropium (Spiriva Respimat) use in asthmatics, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPIRIVA RESPIMAT (tiotropium bromide inhalation spray)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Status: COMPLETED | Results posted: 2019-02-11